# A bridge-like lipid transfer protein is critical for generation of invasive stages in malaria parasites

**Authors:** Andrés Guillén-Samander, Nika Perepelkina, Vendula Horáčková, Hannah M. Behrens, Hely O. Rodriguez Cruz, Joëlle Paolo Mesén-Ramírez, Ana Ribeiro-Holbein, Per Haberkant, Frank Stein, Tobias Spielmann

PMC · DOI: 10.1038/s41467-026-70887-1 · 2026-03-28

## TL;DR

This study identifies a lipid transfer protein critical for the formation of invasive stages in malaria parasites by facilitating lipid transfer from the ER to a key organelle.

## Contribution

The study reveals PfVPS13L1 as a bridge-like lipid transfer protein essential for malaria parasite development.

## Key findings

- PfVPS13L1 bridges the ER with the inner membrane complex (IMC) in malaria parasites.
- Loss of PfVPS13L1 impairs IMC growth and schizogony, reducing parasite progeny.
- The protein mediates bulk lipid transfer required for invasive stage formation.

## Abstract

Malaria blood stages build and maintain an intricate system of membranes during their cycle of rapid growth and schizogony (daughter-cell formation), requiring precise mechanisms of lipid synthesis and trafficking. Lipid transfer proteins (LTPs) at ER membrane contact sites (MCSs) have emerged as key for lipid distribution processes but remain largely unexplored in protozoans. Here we use the ER adapter VAP to identify essential mechanisms of lipid transfer at ER-MCSs in P. falciparum. One PfVAP-interacting LTP is the bridge-like PfVPS13L1, which allows bulk flow of lipids between two apposed membranes. PfVPS13L1 bridges the ER with the nascent inner membrane complex (IMC), a de novo-generated organelle required for schizogony. Its loss-of-function reduces IMC growth and leads to smaller anucleated progeny, impairing schizogony. Our data supports a model in which VPS13L1 is critical for the formation of apicomplexan invasive stages by mediating bulk transfer of lipids from the ER to the growing IMC.

Organelle biogenesis in the rapidly growing malaria parasite requires extensive membrane genesis and remodeling. Here a mechanism to directly supply lipids from the ER to the inner membrane complex (IMC), a de novo formed organelle needed for progeny formation, is shown.

## Linked entities

- **Proteins:** vap (vacuolar peduncle)
- **Diseases:** malaria (MONDO:0005136)

## Full-text entities

- **Genes:** TRERF1 (transcriptional regulating factor 1) [NCBI Gene 55809] {aka BCAR2, HSA277276, RAPA, TREP132, TReP-132, dJ139D8.5}, TFAP2A (transcription factor AP-2 alpha) [NCBI Gene 7020] {aka AP-2, AP-2alpha, AP2TF, BOFS, TFAP2}, TMPRSS13 (transmembrane serine protease 13) [NCBI Gene 84000] {aka MSP, MSPL, MSPS, TMPRSS11}, TUBA1B (tubulin alpha 1b) [NCBI Gene 10376] {aka K-ALPHA-1}, VPS13 (membrane morphogenesis protein VPS13) [NCBI Gene 850619] {aka SOI1, VPT2, YME3}, PMCH (pro-melanin concentrating hormone) [NCBI Gene 5367] {aka MCH, ppMCH}, NMD3 (NMD3 ribosome export adaptor) [NCBI Gene 51068] {aka CGI-07}, OSBP (oxysterol binding protein) [NCBI Gene 5007] {aka OSBP1}, ATG2 (Atg2p) [NCBI Gene 855479] {aka APG2, AUT8, SPO72}, GRIPAP1 (GRIP1 associated protein 1) [NCBI Gene 56850] {aka GRASP-1}, VPS13C (vacuolar protein sorting 13 homolog C) [NCBI Gene 54832] {aka BLTP5C, PARK23}, VPS13D (vacuolar protein sorting 13 homolog D) [NCBI Gene 55187] {aka BLTP5D, SCA24, SCAR4, SCASI}, MORN1 (MORN repeat containing 1) [NCBI Gene 79906], SEC61B (SEC61 translocon subunit beta) [NCBI Gene 10952], LYN (LYN proto-oncogene, Src family tyrosine kinase) [NCBI Gene 4067] {aka JTK8, SAIDV, p53Lyn, p56Lyn}, SF3A2 (splicing factor 3a subunit 2) [NCBI Gene 8175] {aka PRP11, PRPF11, SAP62, SF3a66}, RAB6A (RAB6A, member RAS oncogene family) [NCBI Gene 5870] {aka RAB6}, EREG (epiregulin) [NCBI Gene 2069] {aka EPR, ER, Ep}, VPS13A (vacuolar protein sorting 13 homolog A) [NCBI Gene 23230] {aka BLTP5A, CHAC, CHOREIN}, PAH (phenylalanine hydroxylase) [NCBI Gene 5053] {aka PH, PKU, PKU1}, MSC (musculin) [NCBI Gene 9242] {aka ABF-1, ABF1, MYOR, bHLHa22}
- **Diseases:** Parasitemia (MESH:D018512), SLI (MESH:C567060), Malaria (MESH:D008288)
- **Chemicals:** Gentamycin (MESH:D005839), PI4P (MESH:C037178), TEAB (MESH:C041737), G418 (MESH:C010680), biotin (MESH:D001710), sterol (MESH:D013261), water (MESH:D014867), DTT (MESH:D004229), CaCl2 (MESH:D002122), Alexa Fluor  647 (MESH:C569686), Hoechst 33342 (MESH:C017807), formic acid (MESH:C030544), NaOH (MESH:D012972), HEPES (MESH:D006531), Glucose (MESH:D005947), urea (MESH:D014508), N2 (MESH:D009584), Lipid (MESH:D008055), NaCl (MESH:D012965), sodium cyanoborohydride (MESH:C009282), WR99210 (MESH:C006201), TEMED (MESH:C005798), HCl (MESH:D006851), SDS (MESH:D012967), MgCl2 (MESH:D015636), glutaraldehyde (MESH:D005976), oligonucleotides (MESH:D009841), Alexa Fluor  546 (MESH:C481052), Bodipy (MESH:C095489), imidazopyridine (MESH:C000619660), sodium bicarbonate (MESH:D017693), Tween (MESH:D011136), DPBS (MESH:C012939), iodoacetamide (MESH:D007460), sorbitol (MESH:D013012), CO2 (MESH:D002245), Dihydroethidium (MESH:C067883), sodium acrylate (MESH:C036658), O+ (MESH:D010100), Triton-X-100 (MESH:D017830), Percoll (MESH:C016039), carbon (MESH:D002244), oil (MESH:D009821), peptides (MESH:D010455), N,N'-methylenebisacrylamide (MESH:C021221), KCl (MESH:D011189), PBS (MESH:D007854), acrylamide (MESH:D020106), Amino acids (MESH:D000596), blasticidin S (MESH:C004500), saponin (MESH:D012503), APS (MESH:D000250), acetonitrile (MESH:C032159), silicone (MESH:D012828), formaldehyde (MESH:D005557), hydroxylamine (MESH:D019811), PBS-T (-), sepharose (MESH:D012685), NAD (MESH:D009243)
- **Species:** Plasmodium falciparum (malaria parasite P. falciparum, species) [taxon 5833], Opisthokonta (clade) [taxon 33154], Plasmodium knowlesi (species) [taxon 5850], Homo sapiens (human, species) [taxon 9606], Saccharomyces cerevisiae (baker's yeast, species) [taxon 4932], Plasmodium malariae (species) [taxon 5858], Plasmodium chabaudi (species) [taxon 5825], Plasmodium vivax (malaria parasite P. vivax, species) [taxon 5855], Plasmodium berghei (species) [taxon 5821], Plasmodium yoelii (species) [taxon 5861], Plasmodium falciparum 3D7 (isolate) [taxon 36329], Mus musculus (house mouse, species) [taxon 10090], Plasmodium coatneyi (species) [taxon 208452]
- **Mutations:** M0208L, ATG9A, ATG2A, E4111K, M0530S, ATG2-C, C with 200, T3010L, E740A, Q777A

## Figures

9 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13036008/full.md

---
Source: https://tomesphere.com/paper/PMC13036008